ARS Pharmaceuticals financials
$4.40+6.54%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $84.3M | $89.1M | $30.0K | $1.3M |
| Gross profit | $63.9M | $88.2M | $30.0K | $1.3M |
| Gross margin | 75.8% | 98.9% | 100.0% | 100.0% |
| Operating income | -$179.4M | -$3.1M | -$67.5M | -$35.5M |
| Net income | -$171.3M | $8.0M | -$54.4M | -$34.7M |
| Net margin | −203.3% | 9.0% | −181216.7% | −2635.4% |
| Diluted EPS | $-1.74 | $0.08 | $-0.57 | $-0.87 |
| EBITDA | -$178.1M | -$3.0M | -$67.4M | -$35.2M |
| Operating cash flow | -$170.9M | $13.5M | -$59.3M | -$40.1M |
| Free cash flow | -$171.2M | $13.0M | -$59.4M | -$40.3M |
| Diluted shares | 98.6M | 102.4M | 95.2M | 40.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $41.3M | $50.8M | $71.0M | $210.5M |
| Short-term investments | $203.7M | $263.2M | $157.4M | $63.9M |
| Total debt | $168.5M | $69.4M | $0.00 | $0.00 |
| Total assets | $327.7M | $351.2M | $233.2M | $281.4M |
| Total liabilities | $213.4M | $94.4M | $2.4M | $8.5M |
| Shareholders' equity | $114.3M | $256.8M | $230.8M | $272.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology